A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

Summary

This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.

Timeline

Start

2021-04-29

Primary completion

2024-06-18

Completion

2024-08-02

Outcome

Met primary endpoint

release “CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo.” gene.com ↗

Drugs

Indications